At the helm of this transformative initiative is Peter WT Pisters, M.D., president of MD Anderson, who emphasizes that the current era of oncology is marked by extraordinary potential. “We are at the cusp of a scientific revolution, where the goal to end cancer is no longer a distant dream but a feasible reality,” Dr. Pisters proclaimed. This sentiment resonates deeply within the oncology community, as the campaign’s thrust is grounded firmly in cutting-edge science and innovative clinical applications that converge toward one ultimate objective: to extinguish the scourge of cancer.

“Only Possible Here” is strategically aligned with MD Anderson’s comprehensive institutional strategy and is constructed around three fundamental pillars: expanding reach, expediting scientific breakthroughs, and elevating the patient experience. By doing so, the campaign aims not only to advance the frontiers of experimental oncology but also to transform clinical practice, ensuring that patients benefit from the latest therapeutic modalities in a supportive, patient-centered environment.

Central to the campaign is the planned expansion of MD Anderson’s footprint into Austin, Texas, with groundbreaking scheduled for 2026. This new campus will enable regional access to world-class cancer care, bridging a critical gap in service delivery for Central Texas populations. Bringing comprehensive, personalized oncology care to new geographic locales is anticipated to alleviate disparities in treatment availability and promote earlier diagnosis and intervention, which are crucial determinants of patient outcomes.

One of the campaign’s hallmark scientific endeavors is the Cancer Neuroscience Program, a pioneering initiative at the nexus of oncology and neurobiology. This program seeks to unravel the complex interactions whereby cancer influences the nervous system, leading to debilitating neurological symptoms. By elucidating these pathways, researchers aspire to develop transformative interventions that not only prolong survival but also enhance the quality of life for patients by mitigating cancer-associated neural dysfunction.

Further advancing therapeutic frontiers is the Institute for Cell Therapy Discovery & Innovation, dedicated to the development and refinement of cell-based immunotherapies. A focal point within this institute is chimeric antigen receptor natural killer (CAR NK) cell therapy, an innovative modality harnessing the innate cytotoxicity of NK cells reprogrammed to target malignant cells with precision. This approach holds promise for overcoming resistance mechanisms that limit the efficacy of existing treatments.

In parallel, the Institute for Data Science in Oncology is capitalizing on advances in artificial intelligence and machine learning to decipher the voluminous clinical and molecular datasets accumulated within MD Anderson. By applying sophisticated computational models, the institute aims to identify latent patterns and predictive biomarkers that can guide personalized treatment strategies and accelerate the pace of discovery.

Building on Nobel laureate James P. Allison’s groundbreaking work, the James P. Allison Institute™ continues to champion the promise of immunotherapy, striving to expand its benefits across diverse cancer types. This institute accelerates the translation of fundamental immunological insights into novel therapeutic regimens evaluated through meticulously designed clinical trials, thereby bridging the gap between laboratory science and patient care.

A standout pediatric initiative is the joint venture with Texas Children’s Hospital that birthed the Kinder Children’s Cancer Center, set to open in spring 2026. This center is designed expressly to tackle childhood cancers through a multidisciplinary approach, integrating state-of-the-art research with compassionate, age-appropriate care in a dedicated facility. The center’s mission is unequivocal: to eradicate pediatric cancers by harnessing collaborative expertise and fostering innovation.

Recognizing the crucial role of nursing in oncology outcomes, the Meyers Institute for Oncology Nursing introduces a novel model of support and professional development tailored explicitly to nursing staff. This institute is poised to enhance the knowledge, well-being, and scientific contributions of oncology nurses and nurse scientists, thereby reinforcing the fabric of multidisciplinary cancer care.

Complementing scientific and clinical initiatives is the comprehensive Blueprint for Impact master plan, which envisions transformative facility enhancements. The centerpiece, Patient Care Building 1, will encapsulate 1.8 million square feet of cutting-edge infrastructure designed to accommodate burgeoning patient volumes, integrate advanced diagnostic and therapeutic technologies, and embed healing architecture and art to optimize patient experience and outcomes.

Notably, the campaign includes the nation’s largest oncology patient navigation program, ensuring that every patient has continuous guidance from an oncology nurse navigator across their entire care journey. This program is instrumental in reducing barriers to care, improving adherence to treatment protocols, and fostering survivorship, thereby embodying a holistic approach to cancer management.

The public launch of the campaign was marked by a high-profile event featuring moving patient testimonials and a surprise musical performance by renowned country artist Willie Nelson and his son. Hosted by John Tesh, an MD Anderson survivor and patient himself, the evening underscored the deeply personal and communal dimensions of this historic campaign.

Clarence P. Cazalot, Jr., campaign chair, encapsulated the ethos of the initiative, framing it as a gateway for global participation in one of the most consequential efforts in medical history. “MD Anderson’s unparalleled legacy of pioneering discoveries and treatments, coupled with this unprecedented campaign, positions us to redefine oncology care on a global scale,” he stated.

James L. Gallogly, chair of the Board of Visitors, reinforced this vision by affirming that every contribution of time, talent, or treasure directly propels MD Anderson closer to “Making Cancer History®,” with impacts reverberating far beyond Texas to communities worldwide.

This campaign stands as a beacon of hope and a testament to the power of collective commitment and scientific innovation. By leveraging robust philanthropic support, MD Anderson is poised to accelerate cures, extend survivorship, and ultimately fulfill the enduring promise of ending cancer.

Subject of Research: Comprehensive cancer care, novel immunotherapies, oncology neuroscience, cell therapy, AI-driven oncology data analysis, pediatric cancer treatment.

Article Title: Only Possible Here: MD Anderson Cancer Center Unveils Historic $2.5 Billion Campaign to End Cancer

News Publication Date: November 12, 2025

Web References:

• https://www.mdanderson.org/
• https://onlypossiblehere.mdanderson.org/
• https://faculty.mdanderson.org/profiles/james_allison.html

Image Credits: Michelle Watson

Keywords: Cancer, Immunotherapy, Cell Therapy, Oncology AI, Pediatric Cancer, Neuroscience, Patient Navigation, MD Anderson, Philanthropic Campaign

Pancreatic cancer is notorious for its high mortality rate and is often diagnosed at an advanced stage due to its subtle symptoms and aggressive nature. The clinical scenario often involves the presence of liver metastases, which significantly limits treatment options. However, the concept of conversion therapy—wherein chemotherapy is used to shrink tumors, making them amenable to surgical resection—has begun to gain traction in recent years. The case presented is pivotal as it suggests that patients previously deemed unsuitable for surgery might benefit from this strategy.

Specifically, the research discusses a patient with pancreatic cancer who also had multiple liver lesions. Through a tailored regimen of systemic therapy, the patient’s response to treatment was monitored closely. Evaluations revealed a significant reduction in tumor burden, allowing the patient to transition from a palliative setting to one where surgical intervention could be contemplated. This transformation is particularly noteworthy, as traditional approaches often do not accommodate such aggressive metastatic presentations.

R0 resection refers to the surgical removal of all visible tumor, ensuring no residual cancer cells are left behind. Achieving R0 resection in patients with metastatic disease is a rare but critical outcome that can enhance survival rates. The authors detail the meticulous surgical procedure involved in the R0 resection of the pancreas, highlighting how thorough staging and imaging studies guided surgical planning. Notably, this kind of surgical precision is essential in maximizing patient outcomes.

The implications of successful conversion therapy preceding R0 resection cannot be overstated. It challenges the prevailing notion that pancreatic cancer with liver metastases is merely a terminal diagnosis. Instead, this case suggests that with a multifaceted treatment approach, aggressive management paired with surgical resections can lead to long-term survivorship. The study also emphasizes the importance of multidisciplinary teams in achieving this outcome, as each specialist contributes unique insights to optimize patient care.

Moreover, the researchers address the complexities involved in selecting candidates for this type of aggressive treatment regimen. An extensive understanding of tumor biology, patient health status, and careful monitoring of treatment response are all quintessential aspects that influence decision-making. The physicians involved in this case underwent a series of assessments to determine the optimal timing for surgery, underscoring the need for precision in clinical oncology.

Further along in their analysis, the authors highlight the significance of biomarkers in gauging treatment responses. Emerging genomic and molecular characteristics of tumors could play a role in predicting which patients are likely to benefit from conversion therapy. As research advances, the integration of precision medicine may provide valuable tools in personalizing treatment strategies.

The psychological implications for patients undergoing such intense treatment protocols are also worth considering. The emotional and mental resilience required to navigate through uncertainty and rigorous therapy regimens cannot be underestimated. Survivorship offers hope but can also bring psychological sacrifices, which necessitate comprehensive support systems tailored to patients’ needs throughout their journeys.

In an ever-evolving field like oncology, the importance of continuous clinical trials cannot be understated. This case report emphasizes the need for larger cohort studies to validate the findings and expand upon them. Establishing statistically significant outcomes with diverse populations will enlist more patients into clinical protocols that could prolong life and improve quality.

The authors conclude with a note about the future direction of pancreatic cancer treatment, suggesting that incorporating novel agents and therapeutic strategies could further enhance the effectiveness of conversion therapy. The growing body of research surrounding immunotherapies and targeted therapies presents exciting opportunities that could redefine treatment possibilities.

Innovative surgical techniques alongside medical therapy create new avenues for treatment in patients with historically grim prognoses. This case serves not only as a beacon of hope for patients but also as an impetus for ongoing research and collaboration among experts in the field to dissect complex cases of metastatic disease.

In summary, the case presented by Dong et al. exemplifies how conversion therapy followed by successful R0 resection can change the narrative around pancreatic cancer with liver metastases. It challenges pre-existing benchmarks, provides new insights into patient management, and inspires further research that may ultimately pave the way for improved outcomes in a historically difficult-to-treat cancer.

Subject of Research: Conversion therapy and surgical resection in pancreatic cancer with liver metastases

Article Title: Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report

Article References: Dong, S., Gao, Y., Wang, Z. et al. Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report. J Cancer Res Clin Oncol 151, 200 (2025). https://doi.org/10.1007/s00432-025-06180-3

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06180-3

Keywords: pancreatic cancer, conversion therapy, R0 resection, liver metastases, oncology research, surgical oncology